The UB acquires the UTOX experimental toxicology platform from the Barcelona Science Park
The University of Barcelona, through the Bosch i Gimpera Foundation, has acquired UTOX, the experimental toxicology platform of the Barcelona Science Park.
The objective of this acquisition is for UTOX to become part of the Creatio research group, the center for the production and validation of advanced therapies at the University of Barcelona, a leader in advanced therapies and a member of the TECNIO network.
Thus, from July 1, Creatio will expand its portfolio of services by offering preclinical studies by incorporating the PCB experimental toxicology platform. This acquisition will allow Creatio to offer support and services throughout the drug development chain, from basic research to the production of advanced therapy drugs.
Preclinical toxicological studies make it possible to evaluate the possible adverse effects of new medications and/or other external agents such as chemicals, analyzing how they interact with the body. These studies make it possible to determine the optimal dose, the frequency of administration and side effects, among others, as a necessary step for its future application.
Josep M. Canals, director of Creatio and professor in the Department of Biomedicine at the University of Barcelona, has expressed his satisfaction with this strategic acquisition. “Thanks to the acquisition of the Barcelona Science Park experimental toxicology platform, Creatio now contributes to the entire drug development chain by incorporating toxicology studies that are essential for patient safety.” “We are committed to delivering high-quality results across the ecosystem to ensure the confidence and efficacy of these innovative therapies,” Canals said.
Maria Terrades, CEO of the Barcelona Science Park, has highlighted the importance of the acquisition reinforcing the technical scientific offer that is given from the Park. “It has been crucial that Creatio decided to keep the physical laboratory in the Barcelona Science Park”, stated Terrades. “This will allow Creatio to be close to the companies and entities of the PCB community, strengthening our community and fostering collaboration and knowledge transfer between the public and private sectors.”
Creatio is a translational research center that has the TECNIO seal as a technological development center. With the incorporation of the experimental toxicology platform, Creatio will become one of the most relevant TECNIO centers in the biomedical field. With this expansion, Creatio expects to be a key member in the public and private ecosystem in Catalonia and Spain.